Clinical trials: Newly Diagnosed
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis.
- Conditions
- Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Trial name
- NCT03283917
- Testing
- Daratumumab, Dexamethasone, Ixazomib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.
- Trial name
- NCT04994717
- Testing
- Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
- Where
- 192 sites in United States, Australia and 30 more
- Volunteers
- 303 people
- Sponsor
- Amgen
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult…
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
- Trial name
- AGILE (NCT03173248)
- Testing
- AG-120, Azacitidine
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 146 people
- Sponsor
- Institut de Recherches Internationales Servier
Newly Diagnosed Secondary or High Risk AML
Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
This protocol corresponds to a prospective, multicentre, open label, phase II study designed to evaluate the efficacy of CPX-351 in elderly patients with secondary or high-risk AML.
- Trial name
- LAMVYX (NCT04230239)
- Testing
- CPX-351
- Where
- 12 sites in Spain
- Volunteers
- 59 people
- Sponsor
- PETHEMA Foundation
Newly Diagnosed Multiple Myeloma
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
This is a Phase III open-label, 3-arm, parallel, randomized, controlled trial. The allocation ratio 1:1:1 and outcome assessment are blind to group allocation. Patients will be randomized from 3 arms.
- Trial name
- GEM21menos65 (NCT05558319)
- Testing
- Bortezomib, Isatuximab, Iberdomide
- Where
- 68 sites in Spain
- Volunteers
- 480 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for…
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
- Trial name
- ELDORADO (NCT07247097)
- Testing
- Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Massachusetts General Hospital
Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed multiple myeloma.
- Trial name
- NCT07652138
- Testing
- BCMA/CD19-targeted allogeneic CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Newly Diagnosed Glioblastoma
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
This phase I/II trial evaluates the safety and the immunological efficacy of a cancer vaccine against 2 glioma-associated antigens in newly-diagnosed glioblastomas.
- Trial name
- NAVIG-1 (NCT06622434)
- Testing
- immunization
- Where
- 3 sites in France
- Volunteers
- 35 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Newly Diagnosed Multiple Myeloma, Multiple Myeloma
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible…
- Conditions
- Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
- Trial name
- NCT06348147
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy.
- Trial name
- FASTER (NCT06974786)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ivosidenib when given together with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that is newly diagnosed (previously untreated), has…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04250051
- Testing
- Cytarabine, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy.
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD)
- Trial name
- NCT02632708
- Testing
- AG-120, AG-221, cytarabine
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 153 people
- Sponsor
- Institut de Recherches Internationales Servier
Newly Diagnosed Peripheral T-cell Lymphoma
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
- Trial name
- NCT05976997
- Testing
- Duvelisib, Chidamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Liling Zhang
Recurrent Glioblastoma, Recurrent Gliosarcoma
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma
- Trial name
- NCT04477200
- Testing
- Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Newly Diagnosed Mixed Phenotype Acute Leukemia
A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
This is a prospective, open-label, single-arm, two-cohort Phase 2 clinical study designed to evaluate the efficacy and safety of Bcl-2 Inhibitor combined with azacitidine (with blinatumomab added in B/myeloid subtype) in patients…
- Trial name
- NCT07573670
- Testing
- BCL-2 indibitor, Azacitidine (AZA), Blinatumomab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First Affiliated Hospital of Soochow University
MGMT-Methylated Glioblastoma, Glioblastoma (GBM)
G-CSF After Chemo-radiation in Patients With Glioblastoma
This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation.
- Conditions
- MGMT-Methylated Glioblastoma, Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme
- Trial name
- NCT06649851
- Testing
- Granulocyte Colony Stimulating Factor (G-CSF), Radiation Therapy + Temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia, Newly Diagnosed
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
Silibinin is the major active component of silymarin, a commonly used hepatoprotective agent. It stabilizes hepatocyte membranes, preserves cellular integrity, and accelerates DNA synthesis in liver cells.
- Conditions
- Acute Myeloid Leukemia, Newly Diagnosed, Chemotherapy Effect
- Trial name
- AML (NCT07561892)
- Testing
- daunomycin/Idarubicin+ Silybinin, daunomycin/Idarubicin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University Union Hospital
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
- Trial name
- DREAMM-10 (NCT06679101)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 181 sites in United States, Argentina and 22 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Newly Diagnosed MYC/BCL2 Double-expressor DLBCL
Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
This study is a phase II clinical trial and is divided into three stages. Stage 1: Chemotherapy-free phase. All subjects will receive "Serplulimab, Chidamide, and Rituximab (SCR) therapy".
- Trial name
- SCREEN (NCT07538180)
- Testing
- SCR Regimen Sequential with R-CHOP and Maintenance Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University